Summary and Opinion: It appears Medtronic is hiding an ongoing SEC/DOJ Foreign Corrupt Practices Act (FCPA) investigation, “largely involving historical conduct of third-party distributors, primarily in China.” This article is premium content. To continue reading, please Sign In or Join at the top of this page.